UBS lowered the firm’s price target on AbbVie (ABBV) to $230 from $240 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Earnings Call: New Growth Engines Take Lead
- AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
- AbbVie price target lowered to $228 from $232 at Evercore ISI
- Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
- Midday Fly By: AMD falls despite Q4 beat, Uber reports mixed results